Jubilant Ingrevia Q1: consol PAT +41% YoY to ₹106 Cr as acetyls recovery expands margins

Jubilant Ingrevia opened FY27 with a clear step-up: consolidated revenue rose 25.3% YoY to ₹1,300.3 Cr and net profit climbed 40.9% to ₹105.8 Cr (EPS ₹6.70), with profit growing well ahead of the topline. Net profit margin widened to 8.07% from 7.16% a year ago and the company's own operating margin metric expanded to 11.39% from 9.76%. Sequentially the print was also up — revenue +10.3% and PAT +22.4% over Q4 FY26 — so this is genuine operating improvement rather than a low base, in a business where Q1 is not a seasonal peak. There are no one-off items in the current or year-ago quarters, so the reported ~41% YoY PAT growth is also the underlying number.

The swing is led by the Chemical Intermediates (acetyls) segment, exactly where management had guided a recovery: segment revenue jumped ~38% YoY to ₹524.1 Cr and segment profit multiplied nearly nine-fold to ₹44.0 Cr from ₹5.0 Cr. Nutrition & Health Solutions was the second engine, with revenue up ~36% to ₹243.5 Cr and profit up ~41% to ₹28.3 Cr. Speciality Chemicals lagged — revenue up ~11% but segment profit near-flat at ₹109.1 Cr (+3%) — so the margin gains are concentrated in the other two divisions rather than broad-based.

The stock went into the print at ₹773.65, up 19.8% over the past month of trading.

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.

Against its own guidance, management delivered: the last concall promised sequential revenue and EBITDA growth from Q1 FY27 and at least 20% annual YoY EBITDA growth, and aggregate segment EBIT here rose ~38% YoY — comfortably clearing that bar and confirming the confident tone from the May call. Versus the street, the read is roughly in line: a Univest preview pegged Q1 PAT near ₹112 Cr, and consolidated PAT landed ~5% under that at ₹106 Cr, though revenue came in far above the modest ~₹1,052 Cr some previews carried. Note the basis gap for readers who see the other figure elsewhere: standalone PAT of ₹126.2 Cr grew ~114% YoY (on a weaker ₹59.0 Cr year-ago base) versus the consolidated +41%, because loss-making/low-margin subsidiaries and associates trim roughly ₹20 Cr off the group number.